Abstract: The present invention relates to: a pharmaceutical composition for preventing or treating LDL cholesterol-related diseases, containing a ribosome-binding preparation; a food composition; and a method for preventing or treating LDL cholesterol-related diseases by using the composition. According to the present invention, the ribosome-binding preparation selectively increases the expression of an LDL receptor in intestinal epithelial cells so as to promote LDL absorption in blood and tissue, such that LDL level in the blood can be reduced, thereby being useful for preventing or treating various LDL cholesterol-related diseases including LDL hypercholesterolemia, hyperlipidemia, hypertension and apoplexy.
Type:
Grant
Filed:
June 1, 2017
Date of Patent:
October 13, 2020
Assignee:
PUSAN NATIONAL UNIVERSITY INDUSTRY UNIVERSITY COOPERATION FOUNDATION
Abstract: This present disclosure relates to a method of treating autoimmune, respiratory and/or inflammatory diseases or conditions, e.g., asthma, COPD, rheumatoid arthritis and idiopathic Pulmonary Fibrosis (IPF). The method comprises administering a dual PI3K delta and gamma inhibitor and a corticosteroid. The present invention also relates to pharmaceutical compositions containing a dual PI3K delta and gamma inhibitor and a corticosteroid.
Type:
Grant
Filed:
September 3, 2015
Date of Patent:
September 29, 2020
Assignee:
Rhizen Pharmaceuticals SA
Inventors:
Swaroop K. V. S. Vakkalanka, Srikant Viswanadha
Abstract: Provided is a pharmaceutical composition which contains fulvestrant in an amount of equal to or greater than 8% by mass with respect to the entire mass of the pharmaceutical composition, an aqueous solvent satisfying (1) to (4), and a pharmaceutically acceptable nonaqueous carrier satisfying (A) and (B). (1) Ethanol is contained in an amount of equal to or greater than 8% by mass with respect to the entire mass of the pharmaceutical composition. (2) At least one kind of polyhydric alcohol selected from propylene glycol or 1,3-butylene glycol is contained in an amount of equal to or greater than 3% by mass with respect to the entire mass of the pharmaceutical composition. (3) A content of benzyl alcohol is less than 5% by mass with respect to the entire mass of the pharmaceutical composition. (4) A content of the aqueous solvent is 15% to 50% by mass with respect to the entire mass of the pharmaceutical composition.
Abstract: The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioblastoma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
Type:
Grant
Filed:
May 31, 2017
Date of Patent:
September 1, 2020
Assignee:
Eli Lilly and Company
Inventors:
Jolie Anne Bastian, Jiehao Chen, Jeffrey Daniel Cohen, James Robert Henry, William Thomas McMillen, Bradley Earl Reaman, Almudena Rubio, Daniel Jon Sall, Gaiying Zhao
Abstract: Among other aspects, provided herein are multi-arm polymeric prodrug conjugates of pemetrexed-based compounds. Methods of preparing such conjugates as well as methods of administering the conjugates are also provided. Upon administration to a patient, release of the pemetrexed-based compound is achieved.
Abstract: The present disclosure provides a cleansing composition that includes from about 20% to about 40% by weight of a primary anionic surfactant; from about 10% to about 30% by weight of an amphoacetate; from about 10% to about 30% by weight of a sultaine; and from about 0.5% to about 2% by weight of a fatty acid, wherein the amounts are based upon the total weight of the composition and the composition is free of anionic alkyl sulfates and alkyl ether sulfates.
Type:
Grant
Filed:
April 13, 2016
Date of Patent:
July 14, 2020
Assignee:
RHODIA OPERATIONS
Inventors:
Juie Tanavade, Rajesh Patel, James Griffin
Abstract: The present invention includes compositions and methods for treating or preventing certain dermal disorders including dermal atrophy, pseudoscars, actinic keratosis, seborrheic or actinic keratoses, lentigines, focal areas of dermal thickening, and coarse wrinkles. In certain embodiments, the compositions useful within the invention comprise a therapeutically effective amount of a mTORC1 inhibitor and a dermatologically acceptable carrier.
Type:
Grant
Filed:
September 19, 2016
Date of Patent:
June 30, 2020
Assignee:
Drexel University
Inventors:
Christian Sell, Timothy Nacarelli, Ashley Azar
Abstract: An object of the present invention is to provide novel composition and agent for promoting the production of a brain-derived neurotrophic factor (BDNF) and a novel method for promoting the production of BDNF. The present invention provides a composition for promoting the production of BDNF and an agent for promoting the production of BDNF, each comprising cacao polyphenols. The present invention also provides a method for promoting the production of BDNF, comprising feeding cacao polyphenols in a daily intake which is effective in promoting the production of BDNF for at least 2 weeks.
Abstract: The invention provides liquid formulations of compounds that act at sulfonylurea receptors that are suitable for intravenous and intra-arterial infusion. Compounds active at a sulfonylurea receptor include glibenclamide, tolbutamide, repaglinide, nateglinide, meglitinide, midaglizole, LY397364, LY389382, glyclazide, and glimepiride. Liquid formulations may be concentrated solutions suitable for storage; may be diluted (e.g., dilution of 1:1 or 1:1.2) suitable for bolus injections, and may be further diluted (e.g., dilution of 1:10 or 1:20 or more) for intravenous and intra-arterial infusion over an extended period of time. For example, a liquid formulation may include at least about 0.05 mg/ml glibenclamide in a water-based solution including 40% polyethylene glycol 300, 10% Ethanol, 50% water, at about pH 9. The solution may include a buffer, and is suitable for storage in refrigerator or at room temperature. This solution may be diluted 1:1, or more (e.g., 1:20) without precipitation of the glibenclamide.
Type:
Grant
Filed:
April 8, 2016
Date of Patent:
June 23, 2020
Assignee:
Biogen Chesapeake LLC
Inventors:
Sven Jacobson, Gillian Clarke, Rajinder Matharu
Abstract: The present invention provides a method of inhibiting dependence to an opioid by a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject during opioid therapy. The pharmaceutical composition comprises a) a non-steroidal anti-inflammatory drug (NSAID); and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, cetirizine, salts thereof and combinations thereof.
Abstract: Provided herein is a liquid pesticidal composition which includes an emulsifier component present in an amount from 3 to 35 parts by weight per 100 parts by weight of the liquid pesticidal composition, a pesticide present in an amount from 1 to 90 parts by weight per 100 parts by weight of the composition, and an optional solvent present in an amount from 0 to 90 parts by weight per 100 parts by weight of the composition. The emulsifier component includes an alkaline earth salt of, or amine salt of, a C6-C22 fatty acid along with an alkyl polyglycoside present in an amount from 1 to 20 parts by weight per 100 parts by weight of the composition. The emulsifier component may also include an optional co-emulsifier present in an amount from 0 to 20 parts by weight per 100 parts by weight of the composition.
Abstract: Provided are small molecule inhibitors of ubiquitin specific protease 1 (USP1) activity and methods for their use in treating and characterizing cancers. The small molecule USP1 inhibitors of the invention are particularly useful in the treatment of cancers that are resistant to DNA cross-linking agents.
Type:
Grant
Filed:
November 3, 2016
Date of Patent:
May 19, 2020
Assignees:
Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc.
Inventors:
Alan D. D'Andrea, Gregory D. Cuny, Ross L. Stein, Marcie Glicksman, April Case, Jun Xian, David Wilson, Min Huang
Abstract: A composition to affect an arthropod is described that may include a fatty alcohol, a surface active agent, and a carrier. The composition may include substantially no oil and interrupts production of adipokinetic hormones (AKH) in the arthropod. The composition is introducible to the arthropod via contact or via a liquid application such as a spray. A method of using the composition is described that may include introducing the composition to an environment, causing the arthropod be introduced to the composition, and affecting production of peptides in the arthropod via the composition that affect energy regulation of the arthropod.
Abstract: The invention described herein provides methods for treating a disease or disorder associated with angiotensin receptor signaling in a patient exhibiting elevated levels of ATIR autoantibodies. The invention also provides methods of identifying a patient suffering from a disease or disorder associated with angiotensin receptor signaling that may benefit from treatment with an angiotensin receptor blocker. Patients with elevated levels of ATIR autoantibodies are identified as candidates that particularly benefit from treatment with an angiotensin receptor blocker.
Type:
Grant
Filed:
October 28, 2016
Date of Patent:
May 12, 2020
Assignee:
THE JOHNS HOPKINS UNIVERSITY
Inventors:
Jeremy D. Walston, Peter M. Abadir, Alka Jain, Neal Fedarko
Abstract: The invention describes a long-acting veterinary composition comprising at least one ketoprofen ester prodrug. The composition also comprises at least one veterinary acceptable triglyceride, and optionally, at least one preservative, and optionally, at least one additional veterinary acceptable excipient. The invention also describes a method of treating an animal for fever, pain, and/or inflammation by administering the long-acting composition comprising at least one ketoprofen ester prodrug to the animal in need thereof.
Type:
Grant
Filed:
December 15, 2014
Date of Patent:
April 28, 2020
Assignee:
Zoetis Services LLC
Inventors:
Richard Andrew Ewin, Steven X. Hu, Susan M. Machkovech, Barton H. Manning, Stephen Lee Secreast
Abstract: Pyrazolopyrimidone derivatives and methods of use thereof are described. Specifically, pharmaceutical uses of pyrazolopyrimidone derivatives represented by the general formula (II) and pharmaceutically acceptable salts thereof are described, wherein the definitions of substituents in the general formula (II) are the same as the definitions in the specification. The pyrazolopyrimidone derivatives are useful as gonadotropin releasing hormone (GnRH) antagonists, such as for therapeutic agents for endometriosis.
Abstract: A fungicidal composition comprising a mixture of components (A) and (B), wherein components (A) and (B) are as defined in claim 1, and use of the compositions in agriculture or horticulture for controlling or preventing infestation of plants by phytopathogenic microorganisms, preferably fungi.
Type:
Grant
Filed:
October 10, 2016
Date of Patent:
April 28, 2020
Assignee:
Syngenta Participations AG
Inventors:
Thomas James Hoffman, Sarah Sulzer-Mosse, Kurt Nebel, Fredrik Emil Malcolm Cederbaum, Mathias Blum
Abstract: The present application relates to compounded compositions, methods of making compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions and methods of making compounded compositions comprising one or more anti-infective agents such as mupirocin.
Abstract: The invention pertains to methods that include administering to a subject a transoral dosage form comprising a pharmaceutical carrier and sufentanil, and maintaining a mean pH ranging from about 3.5 to about 5.5 during a dosing period after administration of the transoral dosage form as determined using an in vitro donor media test. Related dosage forms are also disclosed. Also disclosed are transoral dosage forms and related methods, wherein a transoral dosage form may comprise: (1) about 5 to about 1000 micrograms of sufentanil; (2) about 50 micrograms to about 100 milligrams of naloxone; and (3) acidifying material in an amount sufficient to provide a mean pH ranging from about 3.5 to about 5.
Type:
Grant
Filed:
January 12, 2018
Date of Patent:
March 31, 2020
Assignee:
Durect Corporation
Inventors:
Su Il Yum, Jaymin Shah, Sung Yun Kwon, Xiaoping Song